Benzinga | Jan 18, 2022 07:05AM EST

Compugen Expands Announces New US Patent Covering Triple Combination Use With Anti-PD-1 And Anti-TIGIT Antibodies

- Broad method of use patent protection for COM701, a potential first-in-class anti-PVRIG antibody, in triple combination with any anti-PD-1 and any anti-TIGIT antibody for the treatment of cancer

- Further strengthens Compugen's IP portfolio across DNAM axis checkpoint inhibitors





HOLON, Israel, Jan. 18, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the United States Patent and Trademark Office (USPTO) has granted Compugen a new patent covering method of use for COM701, Compugen's potential first-in-class therapeutic antibody targeting PVRIG, or back-up anti-PVRIG antibody, in triple combination with any anti-PD-1 and any anti-TIGIT antibody for the treatment of cancer.

U.S. Patent No. 11,225,523 titled "Triple Combination Antibody Therapies" augments previously issued patents by expanding and protecting the use of COM701 for treating cancer patients, to include the triplet combination of COM701 with any anti-PD-1 antibody and any anti-TIGIT antibody.

"We are focused on maintaining our first mover advantage in the clinic, as the only company with monotherapy, doublet and triplet combination clinical studies evaluating PVRIG, TIGIT, and PD-1. We believe that this patent protection of triple combination regimens further strengthens our leadership position as we continue to execute on our clinical programs based on our DNAM axis hypothesis to treat patients with inflamed and less inflamed tumors who are not responding to current standard of care." said Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen.

U.S. Patent No. 11,225,523 is expected to expire no earlier than August 2037 in the United States.

About COM701